Endocrine system

Glooko to Present Patient Outcomes Showing Impact of Remote Patient Monitoring and Coaching on Glycemic Control in Type 2 Diabetes

Retrieved on:

Friday, June 25, 2021

Branches of biology, Diabetes, Organ systems, Endocrine system, Glooko, Diabetes management, Glucose meter, Type 2 diabetes, Insulin

PALO ALTO, Calif., June 25, 2021 /PRNewswire/ --A study of the use of remote patient monitoring (RPM) with diabetes patients demonstrated improved and sustained glycemic control at 3-, 6- and 12-month intervals among people with type 2 diabetes (PWT2D).

Key Points:

PALO ALTO, Calif., June 25, 2021 /PRNewswire/ --A study of the use of remote patient monitoring (RPM) with diabetes patients demonstrated improved and sustained glycemic control at 3-, 6- and 12-month intervals among people with type 2 diabetes (PWT2D).
The data will be presented during a poster session beginning today at the 81st Scientific Sessions (virtual) of the American Diabetes Association and are sponsored by Glooko, Inc.
Program participants were instructed to regularly sync their blood glucose meters with either a mobile app or a computer-based software during the program.
Synced glucose data were made available to the RPM care teams via a web-based dashboard, and remote coaching was administered either regularly and/or as needed.

MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29

Retrieved on:

Friday, June 25, 2021

Clinical medicine, Organ systems, Endocrine system, Diabetes, Peptide hormones, MannKind Corporation, Thousand Oaks, California, Insulin, Inhalable insulin, Diabetes management

WESTLAKE VILLAGE, Calif., June 25, 2021 /PRNewswire/ --MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present two posters at the American Diabetes Association's virtual 81st Scientific Sessions, June 25-29.

Key Points:

WESTLAKE VILLAGE, Calif., June 25, 2021 /PRNewswire/ --MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present two posters at the American Diabetes Association's virtual 81st Scientific Sessions, June 25-29.
MannKind is also hosting a booth in the virtual Exhibit Hall at the Scientific Sessions.
An insulin regimen that closely mimics physiologic insulin for pediatric patients with type 1 diabetes (T1D) remains a critical goal.
Afrezza an ultra rapid-acting dry-powder prandial insulin is currently indicated to improve glycemic control in adults with T1D or type 2 (T2D) diabetes.

Glooko to Present Patient Outcomes Showing Impact of Remote Patient Monitoring and Coaching on Glycemic Control in Type 2 Diabetes

Retrieved on:

Friday, June 25, 2021

Branches of biology, Diabetes, Organ systems, Endocrine system, Glooko, Diabetes management, Glucose meter, Type 2 diabetes, Insulin

PALO ALTO, Calif., June 25, 2021 /PRNewswire/ --A study of the use of remote patient monitoring (RPM) with diabetes patients demonstrated improved and sustained glycemic control at 3-, 6- and 12-month intervals among people with type 2 diabetes (PWT2D).

Key Points:

PALO ALTO, Calif., June 25, 2021 /PRNewswire/ --A study of the use of remote patient monitoring (RPM) with diabetes patients demonstrated improved and sustained glycemic control at 3-, 6- and 12-month intervals among people with type 2 diabetes (PWT2D).
The data will be presented during a poster session beginning today at the 81st Scientific Sessions (virtual) of the American Diabetes Association and are sponsored by Glooko, Inc.
Program participants were instructed to regularly sync their blood glucose meters with either a mobile app or a computer-based software during the program.
Synced glucose data were made available to the RPM care teams via a web-based dashboard, and remote coaching was administered either regularly and/or as needed.

Remedy+ Is Unleashing the Full Power of Hemp

Retrieved on:

Friday, June 25, 2021

Herbs, Endocrine system, Stress, Sympathetic nervous system, Hemp

This is because Fort Collins, CO based Remedy+ has stealthily been rewriting the script on hemp and the value it can offer people seeking an edge in performance and recovery.

Key Points:

This is because Fort Collins, CO based Remedy+ has stealthily been rewriting the script on hemp and the value it can offer people seeking an edge in performance and recovery.
The thinking is simply this; if you want to control stress and pain, there are countless CBD products on the marketplace to help you with that.
They knew early on that CBD would explode in popularity as people sought natural alternatives for managing stress and pain.
But the pair of entrepreneurs also knew that there was more to the power of CBD than simply ameliorating existing problems.

BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

Retrieved on:

Friday, June 25, 2021

Hormones, Branches of biology, Endocrine system, Insulin

To view the interview segment, please visit: https://www.youtube.com/watch?v=pl3SK0iEV3k

Key Points:

To view the interview segment, please visit: https://www.youtube.com/watch?v=pl3SK0iEV3k
The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions.
In neuro-degenerative disease, BioVie recently acquired the assets of NeurMedix Inc., including NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.
Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained.

City of Hope-Led Research Identifies How the Most Common Type of Breast Cancer Becomes Resistant to Treatment

Retrieved on:

Thursday, June 24, 2021

City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer .

Key Points:

City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer .
About 80% of breast cancer cases are hormone receptor positive, meaning that these cancer cells need estrogen or progesterone to grow, according to the American Cancer Society .
Doctors currently treat people with estrogen receptor positive (ER+) breast cancer using therapy that inhibits both estrogen levels and cell cycle activity.
City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.

Thyroid Cancer Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on:

Thursday, June 24, 2021

Pharmaceutical, Health, Oncology, Anatomy, Thyroid disease, Branches of biology, Organs anatomy), Endocrine diseases, Endocrine system, Glands, Thyroid, Pipeline, Drug pipeline

The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Thyroid cancer - Pipeline Insight, 2021" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Thyroid cancer pipeline landscape.
This segment of the report provides insights about the different Thyroid cancer drugs segregated based on following parameters that define the scope of the report, such as:
There are approx.
Thyroid cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults

Retrieved on:

Wednesday, June 23, 2021

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Ministry of Health, Labour and Welfare (MHLW) has approved the use of AJOVY (fremanezumab) injection for the preventive treatment of migraine in adults in Japan.

Key Points:

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Ministry of Health, Labour and Welfare (MHLW) has approved the use of AJOVY (fremanezumab) injection for the preventive treatment of migraine in adults in Japan.
Driven by our global mission to improve patients lives, we are pleased to offer this new treatment option to people living with migraine in Japan.
In 2020, the two companies announced outcomes from two pivotal studies of AJOVY in people living with episodic and chronic migraine in Japan.
AJOVY is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.

Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event

Retrieved on:

Wednesday, June 23, 2021

European Association for the Study of the Liver, Endocrine system

SALT LAKE CITY, June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data will be presented at The International Liver Congress 2021, the annual meeting of the European Association for the Study of the Liver ("EASL"), Digital Event, on June 23-26, 2021.

Key Points:

SALT LAKE CITY, June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data will be presented at The International Liver Congress 2021, the annual meeting of the European Association for the Study of the Liver ("EASL"), Digital Event, on June 23-26, 2021.
Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154 and LPCN 1107.
In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points.
Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

Integrity Applications Appoints Luis J. Malavé to Board of Directors

Retrieved on:

Tuesday, June 22, 2021

Clinical medicine, Organ systems, Endocrine system, Diabetes, Insulin pump, Diabetes management, Insulin

Luiss impressive track record of working with medical device companies from product development to market expansion and high growth is ideally suited to Integrity, said Paul V. Goode, PhD, member of the Board of Directors.

Key Points:

Luiss impressive track record of working with medical device companies from product development to market expansion and high growth is ideally suited to Integrity, said Paul V. Goode, PhD, member of the Board of Directors.
His expertise in the consumer diabetes space reflects our focus on developing Integrity into a dominant player in the diabetes management industry.
Mr. Malav currently serves as President of EOFLOW CO. Ltd., a company listed on the Korea Stock Exchange that has developed a wearable disposable insulin pump.
Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel.